Figure 1.

Differences between three groups of RRMS patients in baseline sNfL (A) and sGFAP (B) levels. RRMS, relapsing–remitting multiple sclerosis; sNfL, serum neurofilament light chains; sGFAP, serum glial fibrillary acidic protein; KW, Kruskal–Wallis test; NEDA-3, patients free of disease activity at 12 months of ocrelizumab initiation (n = 85); INFL, patients with new relapses and/or radiological activity during follow-up (n = 20); PIRA, patients who had confirmed disability progression in the absence of relapses or new MRI activity at 12 months of ocrelizumab initiation (n = 10).